Friday, October 16, 2026

Back to today

From X

@calvinblissett 1 click

Calvin Blissett on X

$PAHC: 9x cash flow. 26% ROE Animals have to be healthy whether the economy is good or bad, and livestock producers have an economic incentive to spend money on products that reduce mortality, improve feed conversion, increase yield or prevent disease. 22% Adj EBITDA margin. JPM $55 PT. The company operates through the following business divisions: Animal Health division manufactures and sells animal health products such as antibacterial, anticoccidials, nutritional specialty products and vaccines used in the animal health industry to treat or to prevent bacterial diseases to improve the animal’s health. Mineral Nutrition division manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds. Performance Products division manufactures and markets various specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. The most tangible new initiative is the planned closure of Chicago Heights, Illinois. Phibro acquired the facility as part of the Zoetis deal, reviewed its manufacturing network and decided it no longer made economic sense to keep the facility open. Production is expected to cease in summer 2027, affecting roughly 100 employees. Production will be shifted to other Phibro facilities and selected third-party manufacturers. Phibro Animal Health Corporation Management says the point is straightforward: align manufacturing capacity with future needs, improve efficiency and strengthen competitiveness. Phibro Animal Health Corporation The company expects approximately $10m of one-time cash costs and about $10m of capex, with eventual annual EBITDA benefit estimated around $15–20m, largely from FY2028 onward Regulatory optionality: Brazil virginiamycin One of the most interesting hidden catalysts is virginiamycin in Brazil. FY2027 guidance assumes only minimal sales because Phibro has not yet obtained the required therapeutic indications. FY2026 virginiamycin sales in Brazil were roughly $27m. Management explicitly said a favorable regulatory result could therefore provide modest upside to guidance.

2026.42: Home At Last

Stratechery’s weekly bundle covers Apple HomeView and SpaceX’s cellular ambitions.

Is The Market Turning The Page?

CoreWeave’s debt and equity price action is framed as a wake-up call for investors amid a broader market discussion.

PesoRama: Research Flash

PesoRama will reach 54 JOi Dollar Plus stores by November after raising C$28.4 million, funding more than 50 additional Mexican store…

Modine Deep Dive

Modine, soon Modexus Solutions, has a $4 billion hyperscaler cooling contract but must ramp factory output and restore margins as data…

TY · long

Tri-continental CORP

Tri-Continental Corp is presented as a long investment-grade fixed-income idea for portfolios with limited liquidity and diversification.

AppLovin Deep Dive

AppLovin rebuilt its ad model with AXON 2.0, lifting LTM revenue to about $7 billion and margins to 77% as Unity competition threatens…

Constellation: Stars Aligning?

Constellation Brands trades near $127 at roughly 11x next-twelve-month EV/EBIT, with recent business results offsetting concerns over…

Publications we follow

Every publication on this site, hand-picked.

128 publications

Newsletters 107

X accounts we follow

Every account on this site, hand-picked.

90 accounts

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.